Status:
COMPLETED
A Study of Vedolizumab in Adults in Real-World Practice
Lead Sponsor:
Takeda
Conditions:
Colitis, Ulcerative
Crohn Disease
Eligibility:
All Genders
18+ years
Brief Summary
Vedolizumab is a medicine that is currently prescribed for adults with moderately to severely active ulcerative colitis or Crohn's disease. In this study, adults with ulcerative colitis or Crohn's di...
Detailed Description
This is a non-interventional, prospective study of participants with UC or CD who are prescribed and will start vedolizumab in the real word setting for the first time. This study will evaluate the s...
Eligibility Criteria
Inclusion
- Diagnosed with UC or CD
- Firstly prescribed with vedolizumab
Exclusion
- Currently enrolled in or plan to participate in any other clinical trials (that is, interventional study)
- Contraindicated for vedolizumab according to product package insert
Key Trial Info
Start Date :
October 22 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 17 2024
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT04872491
Start Date
October 22 2021
End Date
July 17 2024
Last Update
July 22 2024
Active Locations (40)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China, 100032
2
Peking University First Hospital
Beijing, Beijing Municipality, China, 100034
3
Beijing Friendship Hospital, Capital Medical University
Beijing, Beijing Municipality, China, 100050
4
Peking University Third Hospital
Beijing, Beijing Municipality, China, 100191